Moderna (MRNA) rated 65/100 OVR on MarketMVP. Moderna's mRNA platform is a genuinely novel pharmaceutical technology. Revenue collapsed post-COVID. The pipeline (canc. Tier: C-Tier (Speculative). Revenue: -28%. Beta: 1.0.
Using the MarketMVP OVR system — which translates stocks into sports player ratings for intuitive comparison — MRNA scores 65/100 OVR (C-Tier (Speculative)). The three dimensions: Momentum (45/100) reflects recent price and fundamental trends. Stability (35/100) measures earnings consistency and volatility profile. Value (40/100) assesses price relative to fundamentals and sector peers.
MRNA is compared to different athletes depending on which sport lens you use — but the archetype is consistent: Post-Hype Decline.
What does Moderna (MRNA) do?
Moderna (MRNA) rated 65/100 OVR on MarketMVP. Moderna's mRNA platform is a genuinely novel pharmaceutical technology. Revenue collapsed post-COVID. The pipeline (canc. Tier: C-Tier (Speculative). Revenue: -28%. Beta: 1.0.
What sector is MRNA in?
MRNA is classified in the Healthcare sector on MarketMVP. Healthcare companies develop pharmaceuticals, medical devices, and health services.
Is MRNA in the S&P 500?
MRNA (Moderna) is not a component of the S&P 500 index. Companies outside the S&P 500 may still be significant businesses but have not met the index criteria for size, profitability, or listing requirements.
Who are MRNA's main competitors?
Moderna's main competitors include PFE, BNTX, JNJ, ABBV. In the Healthcare sector, competition is assessed on market share, technology differentiation, pricing power, and customer retention rates.
Is MRNA overvalued?
MRNA has a P/E ratio of N/A (not yet profitable) and a value score of 40/100 on MarketMVP. A mid-range value score suggests the stock is neither obviously cheap nor obviously expensive relative to fundamentals. Valuation is always relative to growth rate and sector context.
What is MRNA's P/E ratio?
MRNA's P/E ratio is N/A (not yet profitable). Without a P/E ratio, the investment thesis depends on future earnings rather than current profitability. MarketMVP's value score of 40/100 contextualises this P/E against revenue growth and sector peers.
What is MRNA's market cap?
Moderna (MRNA) has a market capitalisation of approximately $18B. Mid-cap companies ($10-200B) often offer a balance of growth potential and relative stability. Market cap equals the current share price multiplied by the total number of shares outstanding.
How volatile is MRNA stock?
MRNA has a beta of 1.0, which MarketMVP calls the 'Injury Risk Rating'. Beta near 1.0 means the stock tracks the market closely. Stability score: 35/100.
What is MRNA's beta?
MRNA's beta is 1.0. Beta measures how much a stock moves relative to the overall market. A beta of 1.0 means that historically, for every 1% the market moves, MRNA tends to move approximately 1.0%. Lower beta indicates a more defensive investment that reacts less to market swings.
What is MRNA's dividend?
MRNA does not currently pay a dividend. Growth-oriented companies often reinvest profits into the business rather than paying dividends, prioritising expansion over income.
What is MRNA's revenue growth?
Moderna reported revenue growth of -28% year-over-year. Revenue decline warrants attention — assess whether the trend is temporary (product transition, macro headwinds) or structural.
What is MRNA's OVR rating on MarketMVP?
MRNA is rated 65/100 OVR on MarketMVP — placing it in C-Tier (Speculative). The OVR score combines three dimensions: Momentum (45/100), Stability (35/100), and Value (40/100). Think of it like a FIFA or NBA 2K player rating — a 96 OVR is generational, 80-89 is strong, 65-79 is solid rotation, below 65 is speculative.
Which athlete is MRNA most like?
On MarketMVP, MRNA is compared to different athletes depending on your sport: NFL → Cam Newton, NBA → Derrick Rose, Soccer → Fernando Torres. The archetype is 'Post-Hype Decline' — Moderna (MRNA) rated 65/100 OVR on MarketMVP. Moderna's mRNA platform is a genuinely novel pharmaceu
What percentage of a portfolio should be in MRNA?
Position sizing depends on conviction, risk tolerance, and portfolio construction philosophy. As a general framework: C-Tier stocks like MRNA might represent 1-2% maximum — speculative positions should be sized to limit impact if the thesis fails. No position sizing recommendation is universal — it depends on your complete portfolio context.
Is MRNA a long-term investment?
Moderna has turnaround potential that requires patience and higher risk tolerance. Long-term holding suitability depends on whether you believe the competitive position will remain intact over your investment horizon.
What happens to MRNA stock in a recession?
In economic downturns, MRNA's performance would depend on its business characteristics. Beta of 1.0 suggests roughly market-proportional movement during downturns. Sector fundamentals would be the key driver.
How does MRNA compare to the S&P 500?
MRNA has a MarketMVP OVR of 65/100 placing it in C-Tier — speculative category. Revenue growth of -28% compares to the S&P 500 average of approximately 7-10% annually. Beta of 1.0 compares to the S&P 500 beta of 1.0 — less volatile.
What is MRNA's price target?
MarketMVP does not publish specific price targets — we are an educational platform, not a financial advisory service. Price targets are published by institutional analysts at investment banks and appear on financial platforms like Bloomberg, Yahoo Finance, and MarketBeat. Our OVR system rates MRNA at 65/100 (C-Tier (Speculative)) based on fundamental characteristics rather than price prediction.
What are analysts saying about MRNA?
MarketMVP provides an educational OVR rating of 65/100 for MRNA. For professional analyst ratings and price targets, consult platforms like Bloomberg, Yahoo Finance, Seeking Alpha, or your brokerage's research section. MarketMVP's role is to translate financial characteristics into sports-analogous metrics, not to provide investment advice.
What is MRNA's revenue?
Moderna reported year-over-year revenue growth of -28%. Market capitalisation of $18B provides context for the revenue multiple. For specific revenue figures, quarterly earnings reports (10-Q filings) and annual reports (10-K filings) are publicly available on the SEC EDGAR database and the company's investor relations website.
Does MRNA pay a dividend?
MRNA does not currently pay a dividend. The absence of a dividend typically indicates the company is reinvesting profits into growth initiatives rather than returning capital to shareholders.